Optical system detects angiogenesis in breast cancers
An investigational device shown as a work-in-progress at the RSNA meeting promises to improve the detection of breast cancer by keying off the process of angiogenesis, which can transform an innocuous tumor into a lethal one by triggering the growth of new blood vessels to feed the cancer.
An investigational device shown as a work-in-progress at the RSNA meeting promises to improve the detection of breast cancer by keying off the process of angiogenesis, which can transform an innocuous tumor into a lethal one by triggering the growth of new blood vessels to feed the cancer.
The ComfortScan system being developed by Dobi Medical International uses optical technology to detect abnormal blood vessel proliferation. By producing images related to the physiology of abnormal vascularization, the device offers diagnostic information that cannot be generated by anatomically based breast imaging technologies such as mammography and ultrasound.
Unlike x-ray mammography equipment, ComfortScan does not rely on the delivery of ionizing radiation to generate images of the breast. It uses light-emitting diodes to register blood vessels.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
